Domvanalimab, zimberelimab and FOLFOX shows durable survival in advanced HER2-negative GC/GEJC/EAC

Abemaciclib combined with endocrine therapy improves OS in high-risk HR+, HER2− early breast cancer

Taletrectinib shows efficacy and tolerability in advanced ROS1+ NSCLC previously treated with entrectinib

Giredestrant plus everolimus new option in ER+, HER2– advanced breast cancer, post-CDK4/6 inhibitors

NSCLC brain metastases: TTFields after SRS delays intracranial progression without affecting QoL

Apalutamide and salvage radiotherapy benefits luminal B subtype prostate cancer

ctDNA testing improves detection of treatable metastases compared to standard care in colorectal cancer

ADT with PORT is a good treatment option for men with unfavourable intermediate risk or favourable high risk PC

Bladder cancer updates from the first half of 2025

CURB phase II trial: Tumour burden predicts survival after SBRT in NSCLC oligoprogression

WCLC 2025: Latest in EGFR positive NSCLC

Dose escalation of RG6344 demonstrates safety and promising activity in BRAF V600E solid tumours